Suzhou Alphamab Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2008-11-06
- Employees
- -
- Market Cap
- -
- Website
- http://www.alphamab.com
Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients
- Conditions
- End-Stage Renal Disease Requiring Haemodialysis
- Interventions
- First Posted Date
- 2025-10-01
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT07201467
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing Municipality, China
To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension
- Conditions
- Hypertension
- Interventions
- Drug: 0.9% Sodium Chloride Injection
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT07191899
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, China
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06747416
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
- Conditions
- Hemophilia A Without InhibitorHemophilia B Without Inhibitor
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 125
- Registration Number
- NCT06569108
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2025-09-17
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06547775
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
- Prev
- 1
- 2
- Next
News
Diabetes Pipeline Shows Robust Growth with 200+ Companies Developing Novel Therapies
DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape.